Os Therapies Incorporated (OSTX) Stock Price, Quote & News

Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone l...

Industry: Biotechnology

Sector: Healthcare

Phone: 410 297 7793

Website: ostherapies.com

Address:

115 Pullman Crossing Road, Suite 103, Grasonville, United States

Eagley3k May. 15 at 10:37 PM

$OSTX "the world leader in gene-edited, listeria-based cancer immunotherapies" This sentence is worth $1B in my book.

1 · Reply

smallpower17 May. 15 at 9:41 PM

$OSTX Susquehanna initiates new position in OSTX with 448,000 shares. UBS increases their position in OSTX by 330,000 shares.

0 · Reply

TeaBaggerVance May. 15 at 8:10 PM

$OSTX Earnings Pre-Market on Monday. It’s within the realm of possibilities that they disclose pre-BLA meeting news too. The highest likelihood of when the meeting is to occur was this week or next week. 📈📈📈

1 · Reply

newsfile_corp May. 15 at 8:06 PM

https://nfne.ws/297679 $OSTX @ostherapies #Chemicals #Biotechnology #QuarterlyResults #Investing

0 · Reply

AnssiSuomesta May. 15 at 7:48 PM

$OSTX break 2 next week. Lot's of happening on sights

0 · Reply

Juhanialainen May. 15 at 7:39 PM

$SLS Next week we are with $OSTX riding together to VALHALLA!

2 · Reply

ShawnAscute2024 May. 15 at 7:20 PM

$OSTX. Here is what I bought today and yesterday. It's my last day accumulating OSTX until September. Enjoy the ride with the long-term holders in SLS and OSTX during H2 2026, cheers!

2 · Reply

God5000 May. 15 at 6:27 PM

$OSTX 36 institutions as of today

1 · Reply

ShawnAscute2024 May. 15 at 6:00 PM

$OSTX. Currently, over 0.5M of this in bag, and keep accumulating.

0 · Reply

HedgeFundMgr May. 15 at 5:55 PM

$OSTX yep, smart money knows the news can drop any time.

0 · Reply

OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026

May 14, 2026, 7:30 AM EDT - 1 day ago

OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor

May 12, 2026, 2:35 PM EDT - 3 days ago

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)

Apr 30, 2026, 6:00 AM EDT - 15 days ago

OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma

Apr 27, 2026, 4:01 PM EDT - 18 days ago

OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET

Apr 16, 2026, 7:20 AM EDT - 4 weeks ago

OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes

Apr 13, 2026, 6:00 AM EDT - 4 weeks ago

OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor

Apr 8, 2026, 11:38 AM EDT - 5 weeks ago

OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

Apr 2, 2026, 5:15 PM EDT - 6 weeks ago

OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors

2026-04-01T12:42:57.000Z - 6 weeks ago

OS Therapies price target lowered to $14 from $17 at Lake Street

Mar 31, 2026, 7:40 AM EDT - 6 weeks ago

OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update

Mar 27, 2026, 6:00 AM EDT - 7 weeks ago

OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma

Mar 25, 2026, 6:00 AM EDT - 7 weeks ago

OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma

Mar 9, 2026, 7:40 AM EDT - 2 months ago

OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting

Feb 17, 2026, 6:00 AM EST - 3 months ago

OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma

Feb 4, 2026, 12:45 PM EST - 3 months ago

OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies

Feb 2, 2026, 6:00 AM EST - 3 months ago

OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Jan 15, 2026, 7:00 AM EST - 4 months ago

OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Jan 14, 2026, 7:00 AM EST - 4 months ago

OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary

Jan 12, 2026, 8:01 AM EST - 4 months ago

OS Therapies Enters into Warrant Inducement Agreements

Jan 5, 2026, 7:40 AM EST - 4 months ago

OS Therapies Provides First Half 2026 Corporate Outlook

Dec 15, 2025, 6:00 AM EST - 5 months ago

OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Dec 11, 2025, 10:30 AM EST - 5 months ago

OS Therapies Transcript: Life Sciences Virtual Investor Forum 2025

Dec 9, 2025, 7:40 AM EST - 5 months ago

OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Dec 5, 2025, 8:01 AM EST - 5 months ago

OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility

Nov 25, 2025, 9:21 AM EST - 6 months ago

OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization

Nov 21, 2025, 4:15 PM EST - 6 months ago

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25

Nov 20, 2025, 7:40 AM EST - 6 months ago

OS Therapies to Spinoff OS Animal Health into Standalone Public Company

2025-11-18T14:39:25.000Z - 6 months ago

OS Therapies price target lowered to $17 from $18 at Lake Street

Nov 17, 2025, 6:00 AM EST - 6 months ago

OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 22, 2025, 9:15 AM EDT - 7 months ago

OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Oct 17, 2025, 9:15 AM EDT - 7 months ago

OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Oct 10, 2025, 6:00 AM EDT - 7 months ago

OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

Oct 9, 2025, 7:40 AM EDT - 7 months ago

OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting

Oct 7, 2025, 11:50 AM EDT - 7 months ago

OS Therapies to Participate in Fall 2025 Conferences and Events

Sep 30, 2025, 7:40 AM EDT - 8 months ago

OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update

Sep 19, 2025, 7:40 AM EDT - 8 months ago

OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT

Sep 12, 2025, 7:40 AM EDT - 8 months ago

OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit

Sep 8, 2025, 5:12 PM EDT - 8 months ago

Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)

Sep 3, 2025, 7:40 AM EDT - 9 months ago

OS Therapies to Participate in Upcoming Investor Conferences in September 2025

Sep 2, 2025, 7:40 AM EDT - 9 months ago

OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting

Sep 2, 2025, 6:00 AM EDT - 9 months ago

OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing

Aug 27, 2025, 4:01 PM EDT - 9 months ago

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

Aug 25, 2025, 9:51 PM EDT - 9 months ago

OS Therapies Terminates Equity Line of Credit

Aug 19, 2025, 6:00 AM EDT - 9 months ago

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 5:44 PM EDT - 9 months ago

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

2025-08-08T20:50:15.000Z - 10 months ago

OS Therapies files $100M mixed securities shelf

Aug 7, 2025, 9:00 AM EDT - 10 months ago

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Aug 7, 2025, 6:00 AM EDT - 10 months ago

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

2025-08-04T20:35:57.000Z - 10 months ago

OS Therapies files to sell 3.76M shares of common stock for holders

2025-07-17T19:10:39.000Z - 10 months ago

OS Therapies CEO Paul Romness sees ‘huge upside potential’

2025-07-17T19:10:33.000Z - 10 months ago

OS Therapies hopes to become commercial biotech in early 2026, CEO says

2025-07-17T19:10:27.000Z - 10 months ago

Romness sees potential FDA approval, PVR as key to OS Therapies stock

2025-07-17T19:10:21.000Z - 10 months ago

Meet OS Therapies: Fly exclusive interview with CEO Paul Romness

Jul 14, 2025, 7:40 AM EDT - 10 months ago

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

Jul 10, 2025, 7:40 AM EDT - 11 months ago

OS Therapies Provides Clinical & Global Regulatory Updates

2025-07-03T11:55:08.000Z - 11 months ago

OS Therapies granted End of Phase 2 Meeting by FDA to review OST-HER2 program

Jul 3, 2025, 7:40 AM EDT - 11 months ago

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

2025-06-30T10:05:11.000Z - 11 months ago

OS Therapies reports ‘positive’ results from Phase 2b trial of OST-HER2

Jun 30, 2025, 6:00 AM EDT - 11 months ago

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

2025-06-24T11:56:02.000Z - 11 months ago

OS Therapies receives feedback from FDA Type D Meeting for OST-HER2 trial

2025-06-10T11:45:11.000Z - 1 year ago

OS Therapies partners with Eversana for U.S. commercialization of OST-HER2

2025-05-23T21:15:27.000Z - 1 year ago

OS Therapies files to sell 7.49M shares of common stock for holders

2025-05-16T10:05:35.000Z - 1 year ago

OS Therapies reports Q1 EPS (18c), consensus (8c)

2025-05-15T10:16:07.000Z - 1 year ago

OS Therapies forms subsidiary OS Animal Health to commercialize OST-HER2

2025-05-07T13:17:06.000Z - 1 year ago

OS Therapies announces U.S. patent for Listeria immunotherapy platform

2025-05-07T13:15:18.000Z - 1 year ago

OS Therapies Inc trading resumes

2025-05-07T12:36:46.000Z - 1 year ago

OS Therapies Inc trading halted, news pending

2025-04-22T11:55:59.000Z - 1 year ago

OS Therapies granted FDA meeting for OST-HER2

Eagley3k May. 15 at 10:37 PM

$OSTX "the world leader in gene-edited, listeria-based cancer immunotherapies" This sentence is worth $1B in my book.

1 · Reply

smallpower17 May. 15 at 9:41 PM

$OSTX Susquehanna initiates new position in OSTX with 448,000 shares. UBS increases their position in OSTX by 330,000 shares.

0 · Reply

TeaBaggerVance May. 15 at 8:10 PM

1 · Reply

newsfile_corp May. 15 at 8:06 PM

https://nfne.ws/297679 $OSTX @ostherapies #Chemicals #Biotechnology #QuarterlyResults #Investing

0 · Reply

AnssiSuomesta May. 15 at 7:48 PM

$OSTX break 2 next week. Lot's of happening on sights

0 · Reply

Juhanialainen May. 15 at 7:39 PM

$SLS Next week we are with $OSTX riding together to VALHALLA!

2 · Reply

ShawnAscute2024 May. 15 at 7:20 PM

$OSTX. Here is what I bought today and yesterday. It's my last day accumulating OSTX until September. Enjoy the ride with the long-term holders in SLS and OSTX during H2 2026, cheers!

2 · Reply

God5000 May. 15 at 6:27 PM

$OSTX 36 institutions as of today

1 · Reply

ShawnAscute2024 May. 15 at 6:00 PM

$OSTX. Currently, over 0.5M of this in bag, and keep accumulating.

0 · Reply

HedgeFundMgr May. 15 at 5:55 PM

$OSTX yep, smart money knows the news can drop any time.

0 · Reply

Eagley3k May. 15 at 5:41 PM

$OSTX holding up really well here giving the wide spread red market.

1 · Reply

Juhanialainen May. 15 at 4:19 PM

$SLS As I am 90% in here, I will state that don’t sleep on $OSTX – the founder of Moderna joined them as well as an executive of Guardant Health. OS Therapies is a sleeping giant. My only side hustle. Check it out. Price targets vary from $10–20.

4 · Reply

smallpower17 May. 15 at 3:29 PM

$OSTX https://www.msn.com/en-us/money/topstocks/os-therapies-ostx-price-target-increased-by-16-67-to-14-28/ar-AA23emo3

0 · Reply

Juhanialainen May. 15 at 3:24 PM

$OSTX Ok, next week then. Not in a hurry. We’ll get plenty of catalyst PRs by the end June.

0 · Reply

10XCarolina May. 15 at 2:25 PM

$OSTX The begining...

0 · Reply

biovaluable May. 15 at 1:48 PM

$OSTX the end

1 · Reply

ricksfeed May. 15 at 12:02 PM

$OSTX what time do they typically release?

5 · Reply

HedgeFundMgr May. 15 at 10:36 AM

$OSTX y'all ready? Next week is going to be crazy. Plus, we have the added advantage that the drug actually works, and a $215M PRV waiting in the wings. And a company offering free shares in a new spinoff to those holding OSTX shares. AND that spinoff is touching the one part of veterinary medicine where people spend thousands on their pets. You're still buying, right?

0 · Reply

Eagley3k May. 15 at 3:52 AM

$OSTX https://youtu.be/0Oyzo0_eP4E?si=yNdZ7uMsJerWfD7r An older video but it clearly shows the plan was to out license EX US all along. That explains why we got a word on partnership discussions in today's PR.

0 · Reply

biovaluable May. 15 at 2:28 AM

$OSTX

0 · Reply

HedgeFundMgr May. 15 at 1:15 AM

$OSTX the ticking and the tocking is getting louder . . . Dominoes start dropping very soon. Nothing to fear and much to be excited about.

0 · Reply

biovaluable May. 15 at 12:57 AM

$OSTX OSAH IPO is comming! Last chance to buying!

0 · Reply

Market Cap	74.32M
Revenue (ttm)	0.00
Net Income (ttm)	-28.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	861,700
Avg Vol	709,034
Day's Range	N/A - N/A
Shares Out	39.53M
Stochastic %K	68%
Beta	-1.34
Analysts	Strong Sell
Price Target	$12.00